FI111078B - Menetelmä mometasonifuroaattimonohydraatin valmistamiseksi - Google Patents

Menetelmä mometasonifuroaattimonohydraatin valmistamiseksi Download PDF

Info

Publication number
FI111078B
FI111078B FI931031A FI931031A FI111078B FI 111078 B FI111078 B FI 111078B FI 931031 A FI931031 A FI 931031A FI 931031 A FI931031 A FI 931031A FI 111078 B FI111078 B FI 111078B
Authority
FI
Finland
Prior art keywords
mometasone furoate
water
monohydrate
organic solvent
furoate monohydrate
Prior art date
Application number
FI931031A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931031A (fi
FI931031A0 (fi
Inventor
Pui-Ho Yuen
Charles Eckhart
Teresa Etlinger
Nancy Levine
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI111078(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI931031A publication Critical patent/FI931031A/fi
Publication of FI931031A0 publication Critical patent/FI931031A0/fi
Application granted granted Critical
Publication of FI111078B publication Critical patent/FI111078B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI931031A 1990-09-10 1993-03-09 Menetelmä mometasonifuroaattimonohydraatin valmistamiseksi FI111078B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10
US58023990 1990-09-10
US9106249 1991-09-06
PCT/US1991/006249 WO1992004365A1 (fr) 1990-09-10 1991-09-06 Monohydrate de furoate de mometasone, son procede de fabrication et compositions pharmaceutiques

Publications (3)

Publication Number Publication Date
FI931031A FI931031A (fi) 1993-03-09
FI931031A0 FI931031A0 (fi) 1993-03-09
FI111078B true FI111078B (fi) 2003-05-30

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931031A FI111078B (fi) 1990-09-10 1993-03-09 Menetelmä mometasonifuroaattimonohydraatin valmistamiseksi

Country Status (35)

Country Link
US (1) US6180781B1 (fr)
EP (1) EP0548114B1 (fr)
JP (1) JPH0725789B2 (fr)
KR (1) KR960013445B1 (fr)
CN (1) CN1030920C (fr)
AT (1) ATE113604T1 (fr)
AU (1) AU663471B2 (fr)
BG (1) BG60755B2 (fr)
CA (1) CA2091360C (fr)
CZ (1) CZ281318B6 (fr)
DE (2) DE19875032I2 (fr)
DK (1) DK0548114T5 (fr)
EE (1) EE02962B1 (fr)
ES (1) ES2065701T3 (fr)
FI (1) FI111078B (fr)
HK (1) HK185996A (fr)
HR (1) HRP920383B1 (fr)
HU (1) HU213401B (fr)
IE (1) IE67056B1 (fr)
IL (1) IL99437A (fr)
LU (1) LU90366I2 (fr)
MX (2) MX9203396A (fr)
MY (1) MY106644A (fr)
NL (1) NL980012I2 (fr)
NO (1) NO300548B1 (fr)
NZ (1) NZ239711A (fr)
OA (1) OA09772A (fr)
PH (1) PH30443A (fr)
PL (1) PL165803B1 (fr)
PT (1) PT98905B (fr)
SI (1) SI9111497A (fr)
TW (2) TW272195B (fr)
WO (1) WO1992004365A1 (fr)
YU (1) YU48666B (fr)
ZA (1) ZA917148B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663471B2 (en) * 1990-09-10 1995-10-12 Merck Sharp & Dohme Corp. Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
EP1033991B1 (fr) * 1997-10-09 2002-04-17 Schering Corporation Suspensions de mometasone furoate pour la nebulisation
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
BRPI0413330A (pt) * 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
WO2005051931A2 (fr) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
CA2626628A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
JP2010504323A (ja) * 2006-09-22 2010-02-12 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害物質
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
DK2124944T3 (da) * 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
EP2124943A1 (fr) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
AU663471B2 (en) * 1990-09-10 1995-10-12 Merck Sharp & Dohme Corp. Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Also Published As

Publication number Publication date
CA2091360A1 (fr) 1992-03-11
YU48666B (sh) 1999-06-15
NZ239711A (en) 1992-09-25
CN1059911A (zh) 1992-04-01
CZ281318B6 (cs) 1996-08-14
YU149791A (sh) 1994-01-20
EP0548114B1 (fr) 1994-11-02
KR960013445B1 (ko) 1996-10-05
EP0548114A1 (fr) 1993-06-30
FI931031A (fi) 1993-03-09
HRP920383B1 (en) 2000-04-30
TW229208B (fr) 1994-09-01
CA2091360C (fr) 1997-04-08
SI9111497A (sl) 1998-04-30
ES2065701T3 (es) 1995-02-16
US6180781B1 (en) 2001-01-30
NO300548B1 (no) 1997-06-16
LU90366I2 (fr) 1999-05-05
FI931031A0 (fi) 1993-03-09
IL99437A (en) 1995-05-29
DK0548114T5 (da) 1995-01-30
NO930693L (no) 1993-02-26
CN1030920C (zh) 1996-02-07
IE913155A1 (en) 1992-03-11
TW272195B (fr) 1996-03-11
DE69104991D1 (de) 1994-12-08
NO930693D0 (no) 1993-02-26
HU9300685D0 (en) 1993-06-28
MX9203396A (es) 1992-07-31
JPH05506667A (ja) 1993-09-30
BG60755B2 (bg) 1996-02-29
PL165803B1 (pl) 1995-02-28
DE19875032I2 (de) 2007-04-19
MX9100990A (es) 1992-05-04
WO1992004365A1 (fr) 1992-03-19
ZA917148B (en) 1992-08-26
NL980012I2 (nl) 2004-11-01
ATE113604T1 (de) 1994-11-15
PT98905A (pt) 1992-09-30
IE67056B1 (en) 1996-02-21
JPH0725789B2 (ja) 1995-03-22
HUT64361A (en) 1993-12-28
MY106644A (en) 1995-07-31
IL99437A0 (en) 1992-08-18
NL980012I1 (nl) 1998-05-06
DE69104991T2 (de) 1995-04-20
AU663471B2 (en) 1995-10-12
CZ38393A3 (en) 1994-01-19
HK185996A (en) 1996-10-11
HU213401B (en) 1997-06-30
AU8497491A (en) 1992-03-30
HRP920383A2 (en) 1998-06-30
PT98905B (pt) 1998-08-31
PH30443A (en) 1997-05-09
OA09772A (en) 1993-11-30
EE02962B1 (et) 1997-02-17

Similar Documents

Publication Publication Date Title
FI111078B (fi) Menetelmä mometasonifuroaattimonohydraatin valmistamiseksi
US6127353A (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
EP3549932B1 (fr) Nouvelles formes cristallines d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino} acétique et leur procédé de préparation
BG63338B1 (bg) Кристални производни на n-ацетил невраминова киселина и методи за тяхното получаване
EP4092014A2 (fr) Forme cristalline de fluvatinib ou de méthanesulfonate de fluvatinib et son procédé de préparation
US4456753A (en) Process for the manufacture of highly crystalline sodium cefoperazone
EP3459933A2 (fr) Formes solides d'une composition pharmaceutiquement active
WO2012007453A1 (fr) Composé cristallin de 1-[4-(2-azépan-1-yléthoxy)benzyl]-2-(4-hydroxyphényl)-3-méthyl-1h-indol-5-ol
US10717729B2 (en) Thiamine-organic acid salt
BG61767B1 (bg) Кристали от антимикробно съединение
EP0101170B1 (fr) Procédé pour la préparation de céfopérazone de sodium
JP2663105B2 (ja) １４α−ヒドロキシ−４−アンドロステン−３，６，１７−トリオン水和物結晶及びその製造法
US4419358A (en) Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it
IE44319B1 (en) A crystalline sodium salt of cephacetrile
EP3455229B1 (fr) Nouvelles formes cristallines
CN107868117B (zh) 司坦唑醇糖精盐及其制备方法和应用
FI105034B (fi) Kiteinen etoposidi-4'-fosfaattidietanolaatti
WO2021064166A1 (fr) Formes cristallines de l'acide bempédoïque

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20030010

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 219

Extension date: 20120219

MA Patent expired